Buy Adamax 10 mg + bacteriostatic water
€52.05
Adamax, 10 mg, with bacteriostatic water, is a structure-dependent Semax-related research peptide format. Pharma Research .eu should provide the exact sequence, modification, CoA and LC-MS identity data before European laboratory procurement.
Buy Adamax, 10 mg + Bacteriostatic Water, for Advanced Laboratory Research in Europe
Adamax is an ambiguously defined synthetic peptide designation used by different suppliers for chemically distinct Semax-related analogues. Available catalogues variously describe it as an N-acetylated and C-terminally amidated Semax-derived sequence, an adamantane-modified peptide, or a compound with the sequence Ac-MEHFPGPAG-NHβ. Because these identities are not interchangeable, Pharma Research .eu must confirm the exact structure, sequence, formula and analytical data for the supplied 10 mg batch before procurement.thepeptidecatalog+3
Uncompromising Purity and Analytical Characterisation
The name βAdamaxβ does not currently identify one universally standardised chemical entity. Public product records report substantially different specifications, including:
-
Ac-MEHFPGPAG-NHβ, described as a capped Semax-related nonapeptide. -
A Semax-related peptide carrying an adamantane or adamantyl-glycine modification.
-
Formula and molecular-mass records ranging from approximately 855.97 Da to 1,032.24 Da.
-
No consistently assigned CAS Registry Number for the novel analogue.
These discrepancies are scientifically significant. A product page must not present a single sequence, molecular formula or molecular mass as definitive until the manufacturerβs CoA identifies the exact molecular structure and salt form.b2bpeptides+3
For a research-grade Adamax product, the proposed release target should be β₯99.0% purity by RP-HPLC, subject to confirmation by the actual batch CoA. This is a procurement target rather than a verified claim about an unspecified product. The analytical package should include:
-
RP-HPLC purity percentage, method and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Full sequence and all terminal modifications.
-
Exact description of any adamantane or adamantyl-glycine moiety.
-
Molecular formula and calculated molecular mass for the supplied form.
-
Free-peptide, acetate, trifluoroacetate or other salt-form information.
-
Visual appearance of the lyophilised material.
-
Residual-solvent results from synthesis and purification.
-
Water or residual-moisture content, where measured.
-
Heavy-metal or elemental-impurity results where included in the quality programme.
-
Lot number, manufacture date, retest date and storage requirements.
Several records report the formula Cβ βHββNββOββS and molecular mass near 1,032.24 Da for an Adamax-like adamantane-modified material, while other listings report CββHββNβOβ or CββHβ βNββOβ. These conflicting values demonstrate that the product identity cannot be established from the trade name alone.b2bpeptides+2
The material is expected to be supplied as a white to off-white lyophilised powder, but this appearance should be verified on receipt. Visual inspection can identify gross discolouration, vial damage or visible contamination; it cannot establish chemical identity or purity. Release testing should combine visual assessment with chromatographic purity and mass-spectral identity.
High purity is especially important for a novel modified peptide because possible impurities include truncated sequences, incomplete capping, unmodified Semax, incorrect adamantane incorporation, oxidation products and residual synthesis reagents. These species can alter retention time, ionisation efficiency, solubility and assay response. Non-characterised material is unsuitable for robust quantitative LC-MS, method validation or reproducible comparative research.
Bacteriostatic water is a separate reagent and should have its own label, expiry date, composition and documentation. Its preservatives may influence chromatography, ionisation, adsorption or cellular assay performance.
Principal Laboratory Applications and Research Methodologies
Adamax should be treated as a structure-dependent research reagent rather than as a defined compound until its batch identity is confirmed. All applications should be performed by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
Structural identity and impurity profiling. The primary application is analytical confirmation of the supplied material. LC-MS or LC-HRMS can be used to verify the expected molecular mass, while RP-HPLC can assess purity and separate related substances. If an adamantane modification is claimed, the analytical package should demonstrate that the modification is present in the principal component.
Peptide method development. Once the structure is confirmed, Adamax may support optimisation of chromatographic conditions, precursor-ion selection, product-ion transitions and sample-preparation recovery. A hydrophobic adamantane-containing derivative may behave differently from an unmodified Semax-related peptide, so method parameters should not be transferred without verification.
Stability-indicating research. Laboratories may examine the effects of temperature, light, pH, oxidation, container material and freezeβthaw exposure. Potential changes should be evaluated using both chromatographic and mass-spectral methods, particularly where the peptide contains methionine or a hydrophobic adamantane group.
In vitro neurobiological model development. A verified batch may be used in controlled cell-free or cellular models investigating peptide-associated signalling and neurotrophic pathways. These studies require defined controls, solvent blanks, concentration confirmation and independent confirmation that the prepared material retains the stated identity during the assay.
No molecular concentration should be printed for this product until the exact formula and molecular mass are confirmed. A 10 mg quantity corresponds to different molar amounts depending on whether the material is the shorter capped peptide, an adamantane-modified analogue or another formulation. The nominal mass must also be corrected for purity, water content and counter-ion contribution.
The bacteriostatic-water component should be assessed separately for compatibility with LC-MS and in vitro workflows. Preservatives may produce background signals, ion suppression or cellular effects. A solvent blank and matrix-control strategy should be established before quantitative experimentation.
Compound Stability, Optimal Storage, and Safe Handling Protocols
Because Adamax is not a consistently standardised material, definitive stability claims should not be made without a lot-specific stability programme. Research supplier guidance commonly recommends storing the lyophilised powder sealed, dry, protected from light and at approximately β20Β°C. Prepared solutions are often held at 2β8Β°C for short-term laboratory work or aliquoted and frozen where validated.purepeptides+1
Recommended controls include:
-
Store the unopened lyophilised material at β20Β°C unless the CoA specifies otherwise.
-
Keep the vial tightly closed, dry and protected from direct light.
-
Allow a sealed vial to reach room temperature before opening to minimise condensation.
-
Use low-binding tubes when adsorption may affect recovery.
-
Prepare aliquots if repeated access is expected.
-
Store short-term aqueous solutions at 2β8Β°C only when supported by validation.
-
Use frozen aliquots for longer-term solution storage where stability data support that approach.
-
Avoid repeated freezeβthaw cycles.
-
Record the exact product identity, solvent, concentration, preparation date, operator and storage history.
A hydrophobic modification may affect dissolution, adsorption and precipitation behaviour. The appropriate reconstitution medium must therefore be established experimentally for the confirmed structure. Do not assume that bacteriostatic water will completely dissolve every Adamax variant or provide a suitable medium for every analytical assay.
Reconstitution should be performed using a validated laboratory procedure. Add the selected solvent gradually, allow the powder to hydrate and mix gently. Avoid vigorous agitation unless compatibility has been demonstrated. If visible particles, persistent turbidity or precipitation occurs, the solution should not be introduced into a validated experiment without investigation.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid generating aerosols and prevent contact with skin, eyes and laboratory surfaces. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | Adamax, 10 mg, supplied with bacteriostatic water |
| Chemical identity | Must be confirmed; βAdamaxβ is not a universally standardised structure |
| Reported sequence variant | Ac-MEHFPGPAG-NHβ in some catalogues |
| Reported modified variant | Semax-related peptide with an adamantane or adamantyl-glycine modification |
| IUPAC name | Not safely assignable without the confirmed structure and stereochemistry |
| CAS Registry Number | No consistently unified CAS number; verify the batch documentation |
| Reported molecular formula | Conflicting records include Cβ βHββNββOββS and other formulas; do not publish without CoA confirmation |
| Reported molecular mass | Conflicting catalogue values include approximately 855.97β1,032.24 Da |
| Physical state and colour | Expected white to off-white lyophilised powder; verify on receipt |
| Solubility profile | Structure-dependent; aqueous compatibility must be validated experimentally |
| Typical purity | Proposed target β₯99.0% by RP-HPLC; verify the actual lot-specific result |
| Identity testing | LC-MS, LC-HRMS and RP-HPLC recommended |
| Companion reagent | Bacteriostatic water; volume and formulation should be confirmed on the packaging |
| Long-term storage | Typically β20Β°C, sealed, dry and protected from light; follow the CoA |
The conflicting public records are not minor catalogue discrepancies: they indicate potentially different chemical entities being sold under the same name. Pharma Research .eu should not publish a definitive formula, CAS number, exact mass or IUPAC name until the supplier has provided a sequence- and structure-specific CoA.thepeptidecatalog+3
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position this Adamax format as a specialist European laboratory reagent, but product authority depends on resolving the identity ambiguity before listing or shipment. The product file should include the exact structural designation, sequence, terminal groups, modification description, molecular formula, molecular mass, RP-HPLC chromatogram, mass-spectral identity data, SDS and storage requirements.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
Which Adamax structure is supplied.
-
Whether the product is an unmodified capped Semax-related peptide or an adamantane-modified analogue.
-
Exact sequence, stereochemistry and terminal groups.
-
Formula, molecular mass and salt form.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Compatibility of bacteriostatic water with the confirmed material.
-
Storage, transport and documentation requirements.
Until these details are confirmed, the product should be described as an Adamax-designated research peptide of structure pending verification, not as a chemically definitive compound. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.